Ask in Claude
Ask in ChatGPT
- Podcasts
- Life Sciences
- Business Of Biotech
16 episodes
Business Of Biotech
by Ben Comer · English
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Latest episodes
All episodes
Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
How AbbVie (Sean Kelley) manages neuroscience development risk after discovery—covering clinical decision-making, diagnostics/biomarkers, formulation/device and delivery, portfolio balancing…
9 Nov 2026 · 50m · 19 chaptersTranslating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.
How Grid Therapeutics co-founder/CEO Ned Patz, M.D. translated an academic discovery at Duke into a clinical-stage cancer antibody program, focusing on GT 103 (a completely human-derived antibody…
2 Nov 2026 · 54m · 25 chaptersBioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy
Keith Murphy discusses bioprinting 3D human tissue models for toxicity testing and disease modeling, aiming to improve drug safety decisions and reduce development costs.
26 Oct 2026 · 57m · 21 chaptersInvesting In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
Dr. Bret Bostwick, venture partner at Breyer Capital, discusses investing in CNS breakthroughs and how programmable therapeutics (especially Watson-Crick base-pairing oligonucleotides like…
19 Oct 2026 · 47m · 26 chaptersAI, China, And Biotech Investing With SR One's Simeon George, M.D.
SR1 Capital Management’s biotech investing approach, and how AI and China are reshaping drug development.
12 Oct 2026 · 49m · 21 chaptersReprogramming Cancer And Competing With China With Earli's Cyriac Roeding
Cyriac Roeding (Earli) explains how the company uses AI-designed genetic switches delivered by engineered lipid nanoparticles to make cancer cells produce immune-activating drugs locally, aiming to…
5 Oct 2026 · 1h · 22 chaptersGrowing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.
Advanced Cell’s CEO Philina Lee discusses scaling a radiopharmaceutical company focused on targeted alpha therapies for prostate cancer, including ADVC001 (lead-212/PSMA) clinical differentiation, a…
28 Sep 2026 · 55m · 21 chaptersFinding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.
Moonwalk Biosciences’ obesity strategy using adipose-targeted siRNA (not appetite suppression) to improve on GLP-1s.
21 Sep 2026 · 47m · 22 chaptersBiotech Finance And Investor Update With Independent Board Director Allan Shaw
Biotech financing and investor update—how improving capital markets change investor risk tolerance, what “conviction” and differentiation mean, how to align development milestones with the next…
14 Sep 2026 · 55m · 20 chaptersFunding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
How Sarcomatrix (a late-2022 virtual preclinical biotech) is funding and building a drug development program without institutional capital, using creative financing, heavy outsourcing, and a lean…
7 Sep 2026 · 56m · 23 chaptersPicking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
How Andera Partners (Olivier Litzka) picks biotech and medtech investments across the hype cycle, using a life-cycle portfolio approach (early to commercialization) while navigating policy, AI, and…
31 Aug 2026 · 58m · 24 chaptersBiotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil
Early-stage biotech investing and venture formation at Santé Ventures, led by managing director Omar Khalil.
24 Aug 2026 · 56m · 17 chaptersGetting To A First Product Approval With Celcuity's Brian Sullivan
Cellcuity CEO Brian Sullivan discusses FDA approval (July 14) of RevTorpic (getolalisib; tolisib) for HR-positive/HR2-negative locally advanced or metastatic breast cancer patients without a PIK3CA…
17 Aug 2026 · 50m · 21 chaptersCell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
Encarta’s allogeneic CAR-NK cell therapy for autoimmune disease, plus broader biotech leadership views on patient-centric drug development, cell therapy funding, and fixing U.S.
10 Aug 2026 · 50m · 22 chaptersA Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.
Andrew Lo (MIT finance) and Annette Bakker (Children’s Tumor Foundation) discuss a “rescue model” to repurpose shelved drug candidates for neurofibromatosis (NF) and schwannomatosis, using a…
3 Aug 2026 · 56m · 24 chaptersUsing Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.
How Regeneron Genetics Center (RGC) uses large-scale human genetics (and expanding proteomics/health records) to find disease targets and protective variants, accelerating new therapies and enabling…
27 Jul 2026 · 55m · 20 chaptersWe use cookies.They keep VO running smoothly and help us improve it. Privacy policy